Dudum predicts GLP-1 cash prices will fall to $40-50 a month, AI goes fully in-house, and a new consumer class action emerges
All three of today's items point to the same conclusion. The revenue story (volume, AI and peptides) carries on, but the hidden line of earnings quality is getting worse. Dudum's own price-cut expectation squeezes distribution margins, building all AI in-house adds to capital spending, and a new consumer class action widens the legal exposure.
Read more
In an exclusive interview on CNBC's Squawk Box on 18 Aug, CEO Dudum publicly predicted for the first time that cash-pay GLP-1 prices will fall from $150-200 a month now to $40-50. That further confirms the core tension between growing revenue through branded GLP-1 volume and structural gross-margin compression. In the same interview he made clear that the AI strategy is moving from third-party agents to building everything in-house, and that an AI health coach could launch within 12 months. Separately, a new and independent consumer class action emerged on 18 Aug alleging false statements about privacy. The legal tail has therefore spread from one front (regulators) to 3 (regulators, consumers and securities). The shares closed at $27.39 on 18 Aug (down 4.3%), more than 60% below this year's high of $70.43. The next proof point is still whether Q4 delivers the profit jump, and the risk/reward leans cautious.
Key evidence
- CNBC's Squawk Box, exclusive interview on 18 Aug: CEO Dudum said himself that he ultimately sees GLP-1 prices for cash-paying patients falling from about $150-200 a month now to $40-50 a month, depending on the formulation.
- What HIMS sells now is low-margin branded GLP-1 distribution. If end prices are slashed again to $40-50, the margin room in the distribution leg is squeezed further. That echoes the 12 Aug results, with gross margin of 64% (76% a year earlier, down 12 percentage points) and the CFO conceding it is low for the long term.
- Dudum credits himself for the price cuts, casting them as the result of pressure he put on the system (the compounded-drug era forced out affordable supply). For investors it cuts both ways: better access on the demand side means more volume, but a price war on the supply side means thinner profit per unit.
- In the same interview Dudum made clear the company is investing more to become AI-native, moving from third-party AI agents to building everything in-house. In his words, foundation models detached from closed-loop datasets are not that valuable, and the closed-loop data inside the HIMS medical system is what is truly valuable.
- An AI health coach could launch in as little as 12 months, which Dudum believes can improve medication adherence. It continues the in-house AI Care and smart scale of 7 Aug and the Oura teaser of 23 Jun, and makes the story of closed-loop data as a moat explicit.
- On 18 Aug it emerged that HIMS faces a new consumer class action alleging that it misrepresented user privacy and shared sensitive health data without authorisation. This is separate from the 29 Jul FTC lawsuit: it is a civil class action brought by private plaintiffs.
Show 2 more
- Add the 2 data-breach class actions already logged on 2 May and securities-fraud investigations by at least 4 law firms, and the legal tail has spread from one front (regulators) to 3 (regulators, consumers and securities).
- The 12 Aug results already booked a provision of about $62.5 million for the FTC matter in the income statement, and the new consumer suit means legal-cost exposure keeps widening.
Price action
HIMS closed at $27.39 on 18 Aug (down 4.3%), wiping out the 17 Aug rebound ($28.61) and falling back below its post-earnings range. It is more than 60% below this year's high of $70.43 and down more than 40% year on year.
Catalysts to watch
- AI health coach launching within 12 months (according to Dudum)
- Whether the Q4 profit jump is delivered, the key proof point on earnings quality
- How fast cash-pay GLP-1 prices move towards $40-50 a month, and how gross margin moves with them
- Progress in delivering the peptides and Labs data flywheel
Risks
- Dudum's own price-cut expectation squeezes GLP-1 distribution gross margin ($150-200 falling to $40-50).
- Building all AI in-house adds to R&D and capital spending and keeps weighing on profit in the short term.
- The new, independent consumer class action widens legal exposure.
- The legal tail is advancing on 3 fronts: regulatory (FTC), consumer (class action) and securities (investigations by at least 4 law firms).
- Gross margin in the 12 Aug results was 64% (down 12pp YoY), and the CFO concedes it is low for the long term.
- The shares are more than 60% below this year's high of $70.43 and down more than 40% year on year.
Sources (7)
- CNBC Squawk Box, 18 Aug: exclusive interview with Dudum
- HIMS Q2 earnings, 12 Aug (gross margin 64%)
- FTC lawsuit, 29 Jul ($62.5 million provision)
- Reports of the new consumer class action, 18 Aug
- Logged 2 May: 2 data-breach class actions and securities-fraud investigations by at least 4 law firms
- Launch of in-house AI Care and smart scale, 7 Aug
- Oura teaser, 23 Jun
A brief is a lead for our research, not a verified conclusion or advice.